Contribution of follicular dendritic cells to persistent HIV viremia

Journal of Virology

Volumn 87, Issue 14, 2013, Pages 7893-7901

  Zhang, Jingshan ^a   Perelson, Alan S ^a  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL ARTICLE; DISEASE CARRIER; FOLLICULAR DENDRITIC CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LATENT VIRUS INFECTION; MATHEMATICAL MODEL; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VIRAL CLEARANCE; VIREMIA; VIRION; VIRUS LOAD;

DENDRITIC CELLS, FOLLICULAR; DRUG COMBINATIONS; HIV INFECTIONS; HIV-1; HUMANS; KINETICS; LAMIVUDINE; LOPINAVIR; MODELS, BIOLOGICAL; RITONAVIR; STAVUDINE; VIRAL LOAD; VIREMIA; VIRUS RELEASE;

EID: 84880292188     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00556-13     Document Type: Article

References (62)

1. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
2. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. 1996. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271:1582-1586.
3. Bonhoeffer S, Coffin JM, Nowak MA. 1997. Human immunodeficiency virus drug therapy and virus load. J. Virol. 71:3275-3278.
4. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M, Ho DD. 1997. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387:188-191.
5. Finzi D, Siliciano RF. 1998. Viral dynamics in HIV-1 infection. Cell 93:665-671.
6. Zhang ZQ, Wietgrefe SW, Li Q, Shore MD, Duan L, Reilly C, Lifson JD, Haase AT. 2004. Roles of substrate availability and infection of resting and activated CD4+ T cells in transmission and acute simian immunodeficiency virus infection. Proc. Natl. Acad. Sci. U. S. A. 101:5640-5645.
7. Di Mascio M, Dornadula G, Zhang H, Sullivan J, Xu Y, Kulkosky J, Pomerantz RJ, Perelson AS. 2003. In a subset of subjects on highly active antiretroviral therapy, human immunodeficiency virus type 1 RNA in plasma decays from 50 to <5 copies per milliliter, with a half-life of 6 months. J. Virol. 77:2271-2275.
8. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, Kempf DJ, Mellors JW, Coffin JM, King MS. 2008. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 105:3879-3884.
9. Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, Dewar RL, Planta A, Liu S, Metcalf JA, Mellors JW, Coffin JM. 2003. New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 41:4531-4536.
10. Andrade A, Rosenkranz SL, Cillo AR, Lu D, Daar ES, Jacobson JM, Lederman M, Acosta EP, Campbell T, Feinberg J, Flexner C, Mellors JW, Kuritzkes DR, AIDS Clinical Trials Group A5248 Team. Three distinct phases of HIV-1 RNA decay in treatment-naïve patients receiving r-based antiretroviral therapy: ACTG A5248 study. J. Infect. Dis., in press.
11. Hlavacek WS, Stilianakis NI, Perelson AS. 2000. Influence of follicular dendritic cells on HIV dynamics. Philos. Trans. R. Soc. Lond. B Biol. Sci. 355:1051-1058.
12. Cavert W, Notermans DW, Staskus K, Wietgrefe SW, Zupancic M, Gebhard K, Henry K, Zhang ZQ, Mills R, McDade H, Schuwirth CM, Goudsmit J, Danner SA, Haase AT. 1997. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 276: 960-964.
13. Eisele E, Siliciano RF. 2012. Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity 37:377-388.
14. Bailey JR, Sedaghat AR, Kieffer T, Brennan T, Lee PK, Wind-Rotolo M, Haggerty CM, Kamireddi AR, Liu Y, Lee J, Persaud D, Gallant JE, Cofrancesco J, Jr, Quinn TC, Wilke CO, Ray SC, Siliciano JD, Nettles RE, Siliciano RF. 2006. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J. Virol. 80:6441-6457.
15. Haase AT, Henry K, Zupancic M, Sedgewick G, Faust RA, Melroe H, Cavert W, Gebhard K, Staskus K, Zhang ZQ, Dailey PJ, Balfour HH, Jr, Erice A, Perelson AS. 1996. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science 274:985-989.
16. Cohen J. 2011. HIV/AIDS research. Tissue says blood is misleading, confusing HIV cure efforts. Science 334:1614.
17. Fox CH, Tenner-Racz K, Racz P, Firpo A, Pizzo PA, Fauci AS. 1991. Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. J. Infect. Dis. 164:1051-1057.
18. Laurence J. 1993. Reservoirs of HIV infection or carriage: monocytic, dendritic, follicular dendritic, and B cells. Ann. N. Y. Acad. Sci. 693:52-64.
19. Smith BA, Gartner S, Liu Y, Perelson AS, Stilianakis NI, Keele BF, Kerkering TM, Ferreira-Gonzalez A, Szakal AK, Tew JG, Burton GF. 2001. Persistence of infectious HIV on follicular dendritic cells. J. Immunol. 166:690-696.
20. Keele BF, Tazi L, Gartner S, Liu Y, Burgon TB, Estes JD, Thacker TC, Crandall KA, McArthur JC, Burton GF. 2008. Characterization of the follicular dendritic cell reservoir of human immunodeficiency virus type 1. J. Virol. 82:5548-5561.
21. Pantaleo G, Graziosi C, Demarest JF, Butini L, Montroni M, Fox CH, Orenstein JM, Kotler DP, Fauci AS. 1993. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362:355-358.
22. Spiegel H, Herbst H, Niedobitek G, Foss HD, Stein H. 1992. Follicular dendritic cells are a major reservoir for human immunodeficiency virus type 1 in lymphoid tissues facilitating infection of CD4+ T-helper cells. Am. J. Pathol. 140:15-22.
23. Hicks C, King MS, Gulick RM, White AC, Jr, Eron JJ, Jr, Kessler HA, Benson C, King KR, Murphy RL, Brun SC. 2004. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS 18:775-779.
24. Hlavacek WS, Percus JK, Percus OE, Perelson AS, Wofsy C. 2002. Retention of antigen on follicular dendritic cells and B lymphocytes through complement-mediated multivalent ligand-receptor interactions: theory and application to HIV treatment. Math. Biosci. 176:185-202.
25. Hlavacek WS, Stilianakis NI, Notermans DW, Danner SA, Perelson AS. 2000. Influence of follicular dendritic cells on decay of HIV during antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 97:10966-10971.
26. Hlavacek WS, Wofsy C, Perelson AS. 1999. Dissociation of HIV-1 from follicular dendritic cells during HAART: mathematical analysis. Proc. Natl. Acad. Sci. U. S. A. 96:14681-14686.
27. Mehrishi JN, Zeiller K. 1974. T and B lymphocytes: striking differences in surface membranes. Br. Med. J. 1:360-362.
28. Rasmussen JM, Marquart HV, Rask R, Jepsen HH, Svehag SE. 1988. Quantification of C3dg/Epstein-Barr virus receptors on human B cells and B cell lines. Complement 5:98-107.
29. Tooze JA, Bevan DH. 1991. Decreased expression of complement receptor type 2 (CR2) on neoplastic B cells of chronic lymphocytic leukaemia. Clin. Exp. Immunol. 83:423-429.
30. Reynes M, Aubert JP, Cohen JH, Audouin J, Tricottet V, Diebold J, Kazatchkine MD. 1985. Human follicular dendritic cells express CR1,CR2, and CR3 complement receptor antigens. J. Immunol. 135:2687-2694.
31. Thieblemont N, Haeffner-Cavaillon N, Weiss L, Maillet F, Kazatchkine MD. 1993. Complement activation by gp160 glycoprotein of HIV-1. AIDS Res. Hum. Retroviruses 9:229-233.
32. Gelderblom HR, Hausmann EH, Ozel M, Pauli G, Koch MA. 1987. Fine structure of human immunodeficiency virus (HIV) and immunolocalization of structural proteins. Virology 156:171-176.
33. Wyatt R, Sodroski J. 1998. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 280:1884-1888.
34. Fremeaux-Bacchi V, Bernard I, Maillet F, Mani JC, Fontaine M, Bonnefoy JY, Kazatchkine MD, Fischer E. 1996. Human lymphocytes shed a soluble form of CD21 (the C3dg/Epstein-Barr virus receptor, CR2) that binds iC3b and CD23. Eur. J. Immunol. 26:1497-1503.
35. Kalli KR, Ahearn JM, Fearon DT. 1991. Interaction of iC3b with recombinant isotypic and chimeric forms of CR2. J. Immunol. 147:590-594.
36. Diefenbach RJ, Isenman DE. 1995. Mutation of residues in the C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2. J. Immunol. 154:2303-2320.
37. Gentile M, Adrian T, Scheidler A, Ewald M, Dianzani F, Pauli G, Gelderblom HR. 1994. Determination of the size of HIV using adenovirus type 2 as an internal length marker. J. Virol. Methods 48:43-52.
38. Maldarelli F, Palmer S, King MS, Wiegand A, Polis MA, Mican J, Kovacs JA, Davey RT, Rock-Kress D, Dewar R, Liu S, Metcalf JA, Rehm C, Brun SC, Hanna GJ, Kempf DJ, Coffin JM, Mellors JW. 2007. ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog. 3:e46. doi:10.1371/journal.ppat.0030046.
39. Ramratnam B, Bonhoeffer S, Binley J, Hurley A, Zhang L, Mittler JE, Markowitz M, Moore JP, Perelson AS, Ho DD. 1999. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 354:1782-1785.
40. Gett AV, Hodgkin PD. 2000. A cellular calculus for signal integration by T cells. Nat. Immunol. 1:239-244.
41. Devereux G, Hall AM, Barker RN. 2000. Measurement of T-helper cytokines secreted by cord blood mononuclear cells in response to allergens. J. Immunol. Methods 234:13-22.
42. Bains I, Antia R, Callard R, Yates AJ. 2009. Quantifying the development of the peripheral naive CD4+ T-cell pool in humans. Blood 113:5480-5487.
43. Stafford MA, Corey L, Cao Y, Daar ES, Ho DD, Perelson AS. 2000. Modeling plasma virus concentration during primary HIV infection. J. Theor. Biol. 203:285-301.
44. Moir S, Malaspina A, Li Y, Chun TW, Lowe T, Adelsberger J, Baseler M, Ehler LA, Liu S, Davey RT, Jr, Mican JA, Fauci AS. 2000. B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells. J. Exp. Med. 192:637-646.
45. De Boer RJ, Ribeiro RM, Perelson AS. 2010. Current estimates for HIV-1 production imply rapid viral clearance in lymphoid tissues. PLoS Comput. Biol. 6:e1000906. doi:10.1371/journal.pcbi.1000906.
46. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF. 2003. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat. Med. 9:727-728.
47. Chun TW, Justement JS, Moir S, Hallahan CW, Maenza J, Mullins JI, Collier AC, Corey L, Fauci AS. 2007. Decay of the HIV reservoir in patients receiving antiretroviral therapy for extended periods: implications for eradication of virus. J. Infect. Dis. 195:1762-1764.
48. Gandhi RT, Bosch RJ, Aga E, Albrecht M, Demeter LM, Dykes C, Bastow B, Para M, Lai J, Siliciano RF, Siliciano JD, Eron JJ. 2010. No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. J. Infect. Dis. 201:293-296.
49. Zhang L, Ramratnam B, Tenner-Racz K, He Y, Vesanen M, Lewin S, Talal A, Racz P, Perelson AS, Korber BT, Markowitz M, Ho DD. 1999. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N. Engl. J. Med. 340:1605-1613.
50. Strain MC, Gunthard HF, Havlir DV, Ignacio CC, Smith DM, Leigh-Brown AJ, Macaranas TR, Lam RY, Daly OA, Fischer M, Opravil M, Levine H, Bacheler L, Spina CA, Richman DD, Wong JK. 2003. Heterogeneous clearance rates of long-lived lymphocytes in-fected with HIV: intrinsic stability predicts lifelong persistence. Proc. Natl. Acad. Sci. U. S. A. 100:4819-4824.
51. Fischer M, Joos B, Niederost B, Kaiser P, Hafner R, von Wyl V, Ackermann M, Weber R, Gunthard HF. 2008. Biphasic decay kinetics suggest progressive slowing in turnover of latently HIV-1 infected cells during antiretroviral therapy. Retrovirology 5:107. doi:10.1186/1742-4690-5-107.
52. Archin NM, Vaidya NK, Kuruc JD, Liberty AL, Wiegand A, Kearney MF, Cohen MS, Coffin JM, Bosch RJ, Gay CL, Eron JJ, Margolis DM, Perelson AS. 2012. Immediate antiviral therapy appears to restrict resting CD4+cell HIV-1 infection without accelerating the decay of latent infection. Proc. Natl. Acad. Sci. U. S. A. 109:9523-9528.
53. Kim H, Perelson AS. 2006. Viral and latent reservoir persistence in HIV- 1-infected patients on therapy. PLoS Comput. Biol. 2:e135. doi:10.1371/journal.pcbi.0020135.
54. Rong LB, Perelson AS. 2009. Asymmetric division of activated latently infected cells may explain the decay kinetics of the HIV-1 latent reservoir and intermittent viral blips. Math. Biosci. 217:77-87.
55. Rong LB, Perelson AS. 2009. Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput. Biol. 5:e1000533. doi:10.1371/journal.pcbi.1000533.
56. Jones LE, Perelson AS. 2007. Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 45:483-493.
57. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, Boucher G, Boulassel MR, Ghattas G, Brenchley JM, Schacker TW, Hill BJ, Douek DC, Routy JP, Haddad EK, Sekaly RP. 2009. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15:893-900.
58. Althaus CL, De Boer RJ. 2010. Intracellular transactivation of HIV can account for the decelerating decay of virus load during drug therapy. Mol. Syst. Biol. 6:348. doi:10.1038/msb.2010.4.
59. Isenman DE, Leung E, Mackay JD, Bagby S, van den Elsen JM. 2010. Mutational analyses reveal that the staphylococcal immune evasion molecule Sbi and complement receptor 2 (CR2) share overlapping contact residues on C3d: implications for the controversy regarding the CR2/C3d cocrystal structure. J. Immunol. 184:1946-1955.
60. Hammel M, Sfyroera G, Ricklin D, Magotti P, Lambris JD, Geisbrecht BV. 2007. A structural basis for complement inhibition by Staphylococcus aureus. Nat. Immunol. 8:430-437.
61. Hammel M, Sfyroera G, Pyrpassopoulos S, Ricklin D, Ramyar KX, Pop M, Jin Z, Lambris JD, Geisbrecht BV. 2007. Characterization of Ehp, a secreted complement inhibitory protein from Staphylococcus aureus. J. Biol. Chem. 282:30051-30061.
62. Mitchell DA, Kirby L, Paulin SM, Villiers CL, Sim RB. 2007. Prion protein activates and fixes complement directly via the classical pathway: implications for the mechanism of scrapie agent propagation in lymphoid tissue. Mol. Immunol. 44:2997-3004.